

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PROPOSED CHANGE IN USE OF PROCEEDS

References are made to the announcements of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) dated 16 January 2025, 5 February 2025, 9 February 2025, 10 February 2025, 19 February 2025 and 20 March 2025 (the “**Announcements**”) in relation to, among other things, the Placing and the use of proceeds. Unless otherwise defined, capitalised terms used herein have the same meanings as defined in the Announcements.

As stated in the announcement dated 16 January 2025 that the Company intends to utilise the net proceeds to incorporate a new company (the New Company) together with our business partners. It is clarified that this plan remains unchanged, and the New Company has been incorporated by the Company together with its business partner.

As stated in the announcement of the Company dated 19 February 2025, a total of 135,900,000 Placing Shares have been successfully placed by the Placing Agent to not less than six Placees at the New Placing Price of HK\$0.375 per Placing Share pursuant to the terms and conditions of the Placing Agreements, raising approximately HK\$50.96 million. The net proceeds after deduction of commission and other expenses of the Placing amounted to approximately HK\$50.50 million. As of the date of this announcement, the unutilised net proceeds amounted to approximately RMB36 million (the “**Unutilised Net Proceeds**”). The Board has resolved to change the use of the Unutilised Net Proceeds as follows:

Intended use of Net Proceeds	Amount of Net Proceeds allocated upon the Placing (HK\$ million)	Revised allocation of the Net Proceeds (HK\$ million)	Actual amount of utilised Net Proceeds as at the date of this announcement (HK\$ million)	Revised allocation of Unutilised Net Proceeds (HK\$ million)	Updated expected timeline for use of the unutilized Net Proceeds
For acquiring a medical health software platform	50.5	40.6	14.5 (note 1)	26.1	By 31 December 2025
For the subsequent development of the medical health software platform, general working capital for the medical and elderly care health business and potential investment opportunities.	–	9.9	8.0	1.9	By 31 December 2026
Total	<u>50.5</u>	<u>50.5</u>	<u>22.5</u>	<u>28</u>	

- Approximately HK\$14.5 million has been paid as part of the payment for the acquisition of the medical health software platform, and the remaining HK\$26.1 million is expected to be paid for the acquisition of the medical health software platform before 31 December 2025.

Save as disclosed in this announcement, there are no other changes to the use of the proceeds.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
30 April 2025

As at the date of this announcement, the executive directors of the Company is Sun Li; the non-executive directors of the Company are He Xin, Li Ximing and Li Xueying; the independent non-executive directors of the Company are Wang Yongkang, Gao Chun and Tu Xiangzhen.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.